Muir-Torre syndrome is a genodermatosis in which multiple internal malignancies are associated with cutaneous sebaceous tumours and kerato-acanthomas. A 57-year-old man presented with multiple sebaceous tumours, kerato-acanthomas, verrucous carcinoma of the nose, renal cell and transitional cell carcinomas of the left kidney, adenoma of the colon and a positive family history of colon carcinoma. He was treated with interferon (IFN-α2a) s.c. 3 × 106 U three times a week along with 50 mg isotretinoin daily as well as topical isotretinoin gel. During a follow-up of 29 months, only 1 sebaceous skin tumour developed and was removed, whereas more than 30 such skin tumours had been surgically removed during the last 3 years. No evidence of internal tumour development or recurrence was found. The combination of IFN with retinoids seems to be of promise to prevent tumour development in Muir-Torre syndrome.

Muir EG, Yates Bell AJ, Barlow KA: Multiple primary carcinomata of colon, duodenum and larynx associated with keratoakanthoma of the face. Br J Surg 1967;54:191–195.
Schwartz RA, Torre DP: The Muir-Torre syndrome: A 25-year retrospect. J Am Acad Dermatol 1995;33:90–104.
Cohen PR, Kohn SR, Kurzrock R: Association of sebaceous gland tumors and internal malignancy: The Muir-Torre syndrome. Am J Med 1991;90:606–613.
Rütten A, Burgdorf W, Hügel H, Kutzner H, Hosseiny-Malayeri HR, Friedl W, Propping R, Kruse R: Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: A histopathologic and molecular genetic study. Am J Dermatopathol 1999;21:405–413.
Burgdorf WH, Pitha J, Fahmy A: Muir-Torre syndrome: Histologic spectrum of sebaceous proliferations. Am J Dermatopathol 1986;8:202–208.
Kruse R, Rütten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C, Jungck M, Mathiak M, Ruzicka T, Hartschuh W, Bisceglia M, Friedl W, Propping P: Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 1998;63:63–70.
Kruse R, Lamberti C, Wang Y, Ruelfs C, Bruns A, Esche C, Lehmann P, Ruzicka T, Rütten A, Friedl W, Propping P: Is the mismatch repair deficient type of Muir-Torre syndrome confined to mutations in the hMSH2 gene? Hum Genet 1996;98:747–750.
Kruse R, Rütten A, Hosseiny-Malayeri HR, Günzl H-J, Friedl W, Propping P: A novel germline mutation in the hMLH1 DNA mismatch repair gene in a patient with an isolated cystic sebaceous tumor. J Invest Dermatol 1999;112:117–118.
Honchel R, Halling KC, Schaid DJ, Pittelkow M, Thibodeau SN: Microsatellite instability in Muir-Torre syndrome. Cancer Res 1994;54:1159–1163.
Peris K, Onorati MT, Keller G, Magrini F, Donati P, Muscardin L, Hofler H, Chimenti S: Widespread microsatellite instability in sebaceous tumours of patients with the Muir-Torre syndrome. Br J Dermatol 1997;137:356–360.
Akhtar S, Oza KK, Khan, SA, Wright J: Muir-Torre syndrome: Case report of a patient with concurrent jejunal and uretral cancer and a review of the literature. J Am Acad Dermatol 1999;41:681–686.
Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P: Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/ Fas)-CD95 ligand induced suicide. J Clin Invest 1997;199:2691–2696.
Gordon KB, Roenigk HH, Gendleman M: Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa: Efficacy of combination chemotherapy. Arch Dermatol 1997;133:691–693.
Shaw JC, White CR Jr: Treatment of multiple keratoacanthomas with oral isotretinoin. J Am Acad Dermatol 1986;15:1079–1082.
Spielvogel RL, DeVillez RL, Roberts LC: Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol 1985;12:475–480.
Marcusson JA, Bjarnasson B, Bos AM: Isotretinoin for sebaceous skin lesions in Muir-Torre syndrome: A case report. Acta Derm Venereol 1998;78:479–480.
Hsu M-C: Systemic treatment of neoplastic conditions with retinoids. J Am Acad Dermatol 1998;39:108–113.
Evans TR, Kaye SB: Retinoids: Present role and future potential. Br J Cancer 1999;80:1–8.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.